Marksans Pharma share price today

Marksans Pharma Ltd's share price was ₹301.65 at the close on 4 November 2026. It has been rising for 23 weeks. That is 15.2% above its average price over the last 200 trading days. In the last 52 weeks it traded between ₹163 and ₹337, and at that close it sat 80% of the way up from that low.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Marksans Pharma Ltd is in stage 2. The phase helps read everything below.

Over the past 13 weeks it has done worse than the NIFTY 500, and it has been behind for 1 week running.

Over the last 11 years the share price moved +496% while the NIFTY 500 moved +251%, so it is ahead of the index over that whole period. It was last ahead over 13 weeks in the week of 30 October 2026. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

Three changes stood out: foreign funds (FIIs) raised their stake for 3 quarters in a row, revenue up on a year earlier for 11 quarters in a row (every quarter we can compare) and best operating margin in 15 quarters.

1. Foreign funds (FIIs) raised their stake for 3 quarters in a row

   From 8.1% to 19.1% of the company by the September 2026 quarter.

2. Revenue up on a year earlier for 11 quarters in a row (every quarter we can compare)

   In the June 2026 quarter revenue was ₹841 crore, +35.6% on a year earlier.

   Why: Revenue rose because UK sales grew on their own and the QliniQ business it bought added sales.

   Next results: check whether sales in the September quarter are higher than the June quarter, as management said they would be.

   From the earnings call on 13 Aug 2026.

3. Best operating margin in 15 quarters

   Operating margin was 25% in the June 2026 quarter, against 16% a year earlier.

   Why: Higher freight and raw material costs partly offset this.

   From the earnings call on 13 Aug 2026.

For April to June 2026 (the quarter ended 30 June 2026), Marksans Pharma reported revenue of ₹841 crore, up 35.6% from ₹620 crore a year earlier, and a profit of ₹159 crore, up 174.1% from ₹58.0 crore.

Marksans Pharma results: April to June 2026 against a year earlier

The next results, for July to September 2026, are due by 14 November 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter).

Marksans Pharma's management discussed these results on a call held on 13 August 2026; what it said is further down this page.

From the company's reported quarterly results (quarter ended 30 June 2026). Revenue and profit in ₹ crore.

Marksans Pharma closed at ₹301.65 on 4 November 2026, up 64.9% from ₹182.95 a year earlier (7 November 2025) and up 348.6% over five years. Its highest weekly close since March 2016 was ₹342.75 on 29 November 2024.

Marksans Pharma share price: then and now

Weekly closing prices. Each change is the move from that price to the 4 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes.

563 weekly closes from 11 March 2016 to 4 November 2026.

4 Nov 2026: Marksans Pharma closed at ₹301.65, down 1.6% on the week and down 7.2% on the month. Our read, 22 Aug 2026: The latest quarter combined faster revenue growth with a higher operating margin, while Europe became a larger contributor and cash generation improved.

Earlier

• 20 Aug 2026: ex-date for a dividend of ₹0.90 a share.
• 13 Aug 2026: Marksans Pharma held its results call for April to June 2026. Management guided: FY27 revenue growth 15-20% and operating margin 20-21% retained; 21-22% operating margin achievable by year-end, with gross margin around 55-56% viewed as sustainable.
• Results for April to June 2026: Revenue up 35.6% and profit up 174.1% on a year earlier.

Our read of the business

The latest quarter combined faster revenue growth with a higher operating margin, while Europe became a larger contributor and cash generation improved.

April to June 2026: Revenue and profit rose sharply while the margin moved further above the formal full-year framework.

Our read after the April to June 2026 results, written 22 August 2026.

Marksans Pharma paid ₹0.90 a share in regular dividends in the 12 months to 5 November 2026 (1 payment), a yield of 0.30% at the ₹301.65 close on 4 November 2026. The last was a dividend of ₹0.90 a share, ex-date 20 August 2026.

Marksans Pharma dividends since 1 April 2021

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date. The record date is the same day as the ex-date for every payment here.

Yes. Marksans Pharma Ltd paid out 10% of its profit as dividends in FY26, and it paid a dividend in each of its last 13 reported years.

From the NSE corporate-actions record, read 5 November 2026.

On the call for April to June 2026, held on 13 August 2026, Marksans Pharma's management guided: FY27 revenue growth 15-20% and operating margin 20-21% retained; 21-22% operating margin achievable by year-end, with gross margin around 55-56% viewed as sustainable.

“We are now working toward 300 million, and then we will probably look at 400 million over a horizon of perhaps 5 years. Our immediate objective is first to reach our next benchmark of 300 million in the US.”Mark Saldanha, on the call for April to June 2026

What management guided

• QliniQ FY27 revenue around ₹150-175 crore, also discussed at EUR 14-15 million; total Europe approximately ₹180 crore and current growth pace called sustainable.
• Q2 revenue expected above Q1 and Q3 likely strongest; Germany revenue expected early Q3, Ireland next financial year, and ANZ momentum should build.
• Revenue goal ₹4,000 crore within next two years; Europe planned at approximately ₹1,000 crore within five years through further acquisitions.
• US business revenue objective of 300 million initially, then 400 million over approximately five years; OTC remains core, with mix potentially moving toward 85-15% OTC/RX.

Management’s own plans and goals, from our notes of the call. A plan is not a result.

Source: the call transcript.

From the call for April to June 2026, 13 August 2026.

Management said US order-book reflection would occur in the next financial year after commercialization.

• Management had previously expected part of the US order book to begin execution in the reported quarter sequence. ✓ fact

Our read after the April to June 2026 results, written 22 August 2026.

A sequential margin decline that takes operating margin below the formal full-year range while Europe and Teva fail to add visible revenue would show that the current earnings level was inventory- and mix-assisted rather than a durable operating change.

Each change stops working if

• : Teva revenue or utilization does not improve across two reported quarters despite the stated product pipeline.
• : Germany produces no reported revenue by the stated launch window or acquired European revenue does not convert into sustained consolidated growth.
• : North America growth falls below the company framework while price erosion moves beyond the range management described.

The main risks

• : Input-cost and freight pressure may arrive after the inventory buffer unwinds. ✓ fact
• : Working-capital growth remains a red dig until collection and inventory terms are disclosed. ✓ fact
• : Management has changed the timing or framing of capacity, order-book and margin guidance. ✓ fact
• : Europe execution may be slower than the acquisition and setup narrative implies. ✓ fact

Our read after the April to June 2026 results, written 22 August 2026.

When Marksans Pharma reports July to September 2026, these are the 3 checks that show whether the story is still on course. First: German platform first revenue - check performance against the indicated near-term launch timing.

Marksans Pharma is on 3 of our India lists: Momentum stocks, Small & mid cap stocks and Pharma stocks.

Marksans Pharma Ltd earned ₹159 Cr of net profit in the Jun 2026 quarter, +174.1% on the same quarter a year earlier. That is the 4th quarter in a row of profit growth. Full-year FY26 profit was ₹420 Cr. Over 10 years profit has grown 17.6% a year on average. That is 18.9% of the quarter's revenue.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

The same quarter a year earlier earned ₹58.0 Cr.

For the full year, FY26 profit was ₹420 Cr (+9.7% on the year before).

Why profit moved: revenue changed +35.6% on a year earlier and the margin moved +9.0 percentage points. Most of the change came from keeping more of each sale.

On average over the last four quarters, profit changed +61.8% and revenue +19.8%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra rupee of revenue adds more to profit.

Marksans Pharma Ltd reported ₹841 Cr of revenue in the Jun 2026 quarter, +35.6% on the same quarter a year earlier. That is the 12th quarter in a row with growth on the year before. Over 10 years it has grown 12.7% a year on average. The last full year, FY26, came in at ₹2,951 Cr.

Revenue is everything the company billed its customers in the period.

Why this happened. The value-chain climb is visible in the wider regulated-market footprint: the latest call attributes a large Europe contribution to organic UK growth and the QliniQ consolidation, with Germany scheduled to begin contributing after setup.

The last four reported quarters add to ₹3,171 Cr.

FY26 revenue was ₹2,951 Cr, +12.5% on the year before.

Recent pace: the last four quarters grew +19.8% on average, against 12.7% a year over the longer run, so this year is growing faster than its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew +19.6%, against +18.2% a year over the last 8 quarters (stabilising); profit over the last 12 months grew +48.0%, against +24.9% a year (accelerating).

Marksans Pharma Ltd's operating margin was 25.0% in the Jun 2026 quarter, 9.0 percentage points higher than the same quarter a year ago. Across 13 years it has been between 6.0% and 25.0%. The latest quarter is within that range.

Operating margin is what is left from every ₹100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Why this happened. The operating-leverage catapult applies because management described unused Teva capacity and further volume potential before major expansion capex is needed. The current quarter’s higher operating margin is consistent with that mechanism, although it does not prove the margin is permanent.

Why the margin moved: operating margin changed +9.2 percentage points on the year while gross margin changed +1.4 points. So the gain came mostly from costs below the gross margin, such as staff and overheads, measured against sales.

Over the last 3 years, 80% of Marksans Pharma Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹458 Cr of operating cash against ₹420 Cr of profit. After ₹193 Cr of spending on assets, ₹265 Cr was left over as free cash.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Why this happened. Management reported cash generation and net cash after the QliniQ payment, and said funds are intended for inorganic growth. This is optionality rather than a base-case contribution because no further transaction size or closing date was committed.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why 80% of profit came in as cash: the cash cycle got 44 days longer between FY21 and FY26, so more of each rupee of profit waits in the business before it arrives.

What to look at next: the bigger use of cash is spending on new assets, at 3.4× depreciation over three years. The next section checks what that spending is building.

Marksans Pharma Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 261 days in FY26, up from 217 days in FY21. It spent ₹863 Cr on assets over the last 3 years. Customers take 80 days to pay, and stock sits for 278 days on average.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

At FY26 sales of ₹2,951 Cr, each day of that cycle ties up about ₹8.1 Cr, so roughly ₹2,110 Cr is tied up in the business at any time.

FY26: customers took 80 days to pay and stock sat for 278 days, about 9.1 months of sales sitting as stock, for a full cycle of 261 days, longer than FY21's 217.

The full loop: cash goes out to suppliers and production on day 0. Stock sits for 278 days. Customers pay about 80 days after that. Suppliers are paid at 96 days. Together that makes the 261-day cycle.

Spending on assets: ₹863 Cr over the last 3 years, against ₹256 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹59.0 Cr (FY26): assets paid for that are not earning yet.

In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns.

Marksans Pharma Ltd's P/E is 26.4×, in the middle of its own history: higher than 67% of past readings. Its usual P/E (the middle reading) is 21.4×, over 11 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.